ProPhase Labs, Inc. (PRPH)
USD 0.29
(2.28%)
USD 0.29
(2.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 19.23 Million USD | 994.88% |
| 2022 | -2.14 Million USD | -133.1% |
| 2021 | 6.49 Million USD | -17.87% |
| 2020 | 7.9 Million USD | 1921.66% |
| 2019 | -434 Thousand USD | 72.07% |
| 2018 | -1.55 Million USD | 51.02% |
| 2017 | -3.17 Million USD | -402.48% |
| 2016 | 1.04 Million USD | 629.8% |
| 2015 | -198 Thousand USD | 92.99% |
| 2014 | -2.82 Million USD | -96.52% |
| 2013 | -1.43 Million USD | -428.68% |
| 2012 | -272 Thousand USD | 95.09% |
| 2011 | -5.54 Million USD | 32.69% |
| 2010 | -8.23 Million USD | 35.69% |
| 2009 | -12.8 Million USD | -7.06% |
| 2008 | -11.95 Million USD | 25.67% |
| 2007 | -16.08 Million USD | 9.41% |
| 2006 | -17.75 Million USD | -15.15% |
| 2005 | -15.42 Million USD | -34.4% |
| 2004 | -11.47 Million USD | -0.72% |
| 2003 | -11.39 Million USD | 11.67% |
| 2002 | -12.89 Million USD | -32.4% |
| 2001 | -9.74 Million USD | 14.3% |
| 2000 | -11.36 Million USD | 18.82% |
| 1999 | -14 Million USD | 50.53% |
| 1998 | -28.3 Million USD | -10.98% |
| 1997 | -25.5 Million USD | -6275.0% |
| 1996 | -400 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 24.45 Million USD | 15.91% |
| 2024 Q1 | 21.6 Million USD | 12.33% |
| 2023 Q2 | 12.66 Million USD | 182.1% |
| 2023 Q4 | 19.23 Million USD | 5.87% |
| 2023 Q1 | 4.49 Million USD | 308.98% |
| 2023 FY | 19.23 Million USD | 994.88% |
| 2023 Q3 | 18.16 Million USD | 43.38% |
| 2022 Q4 | -2.14 Million USD | 78.85% |
| 2022 FY | -2.14 Million USD | -133.1% |
| 2022 Q3 | -10.16 Million USD | 9.65% |
| 2022 Q2 | -11.24 Million USD | 13.51% |
| 2022 Q1 | -13 Million USD | -300.28% |
| 2021 Q1 | -17.9 Million USD | -326.44% |
| 2021 FY | 6.49 Million USD | -17.87% |
| 2021 Q4 | 6.49 Million USD | 0.34% |
| 2021 Q3 | 6.47 Million USD | 335.57% |
| 2021 Q2 | -2.74 Million USD | 84.66% |
| 2020 Q1 | 143 Thousand USD | -70.93% |
| 2020 Q3 | -870 Thousand USD | -208.48% |
| 2020 Q4 | 7.9 Million USD | 1008.74% |
| 2020 FY | 7.9 Million USD | 1921.66% |
| 2020 Q2 | 802 Thousand USD | 460.84% |
| 2019 Q2 | 3.63 Million USD | 104.38% |
| 2019 Q1 | 1.77 Million USD | 214.48% |
| 2019 Q3 | 2.79 Million USD | -23.21% |
| 2019 Q4 | 492 Thousand USD | -82.38% |
| 2019 FY | -434 Thousand USD | 72.07% |
| 2018 Q3 | -2.26 Million USD | 38.09% |
| 2018 Q2 | -3.66 Million USD | -8.21% |
| 2018 Q1 | -3.38 Million USD | -6.74% |
| 2018 Q4 | -1.55 Million USD | 31.51% |
| 2018 FY | -1.55 Million USD | 51.02% |
| 2017 Q3 | -3.89 Million USD | 89.55% |
| 2017 FY | -3.17 Million USD | -402.48% |
| 2017 Q2 | -37.28 Million USD | 12.9% |
| 2017 Q1 | -42.8 Million USD | -4180.08% |
| 2017 Q4 | -3.17 Million USD | 18.58% |
| 2016 Q2 | 329 Thousand USD | 133.4% |
| 2016 Q4 | 1.04 Million USD | -5.41% |
| 2016 Q3 | 1.1 Million USD | 237.08% |
| 2016 FY | 1.04 Million USD | 629.8% |
| 2016 Q1 | -985 Thousand USD | -397.47% |
| 2015 Q1 | -4.92 Million USD | -74.13% |
| 2015 FY | -198 Thousand USD | 92.99% |
| 2015 Q4 | -198 Thousand USD | 83.98% |
| 2015 Q3 | -1.23 Million USD | 66.24% |
| 2015 Q2 | -3.66 Million USD | 25.6% |
| 2014 Q4 | -2.82 Million USD | 42.94% |
| 2014 Q2 | -7.15 Million USD | -34.42% |
| 2014 Q1 | -5.31 Million USD | -269.89% |
| 2014 Q3 | -4.95 Million USD | 30.73% |
| 2014 FY | -2.82 Million USD | -96.52% |
| 2013 Q4 | -1.43 Million USD | -218.85% |
| 2013 Q3 | -451 Thousand USD | 88.0% |
| 2013 Q2 | -3.75 Million USD | 11.28% |
| 2013 Q1 | -4.23 Million USD | -1457.35% |
| 2013 FY | -1.43 Million USD | -428.68% |
| 2012 FY | -272 Thousand USD | 95.09% |
| 2012 Q1 | -6.26 Million USD | -13.12% |
| 2012 Q2 | -4.61 Million USD | 26.45% |
| 2012 Q3 | -1.81 Million USD | 60.63% |
| 2012 Q4 | -272 Thousand USD | 85.01% |
| 2011 FY | -5.54 Million USD | 32.69% |
| 2011 Q1 | -9.58 Million USD | -16.45% |
| 2011 Q2 | -8.74 Million USD | 8.79% |
| 2011 Q3 | -4.61 Million USD | 47.2% |
| 2011 Q4 | -5.54 Million USD | -20.04% |
| 2010 Q2 | -11.16 Million USD | 9.63% |
| 2010 Q3 | -8.7 Million USD | 22.02% |
| 2010 Q1 | -12.35 Million USD | 3.51% |
| 2010 Q4 | -8.23 Million USD | 5.43% |
| 2010 FY | -8.23 Million USD | 35.69% |
| 2009 Q4 | -12.8 Million USD | -43.11% |
| 2009 Q2 | -9.21 Million USD | 24.73% |
| 2009 Q1 | -12.24 Million USD | -2.4% |
| 2009 Q3 | -8.94 Million USD | 2.95% |
| 2009 FY | -12.8 Million USD | -7.06% |
| 2008 Q3 | -10.88 Million USD | 24.31% |
| 2008 Q1 | -16.26 Million USD | -1.12% |
| 2008 Q2 | -14.37 Million USD | 11.62% |
| 2008 FY | -11.95 Million USD | 25.67% |
| 2008 Q4 | -11.95 Million USD | -9.89% |
| 2007 Q3 | -12.48 Million USD | 21.2% |
| 2007 FY | -16.08 Million USD | 9.41% |
| 2007 Q2 | -15.84 Million USD | 17.38% |
| 2007 Q1 | -19.17 Million USD | -7.99% |
| 2007 Q4 | -16.08 Million USD | -28.85% |
| 2006 Q2 | -16.06 Million USD | 4.79% |
| 2006 Q3 | -13.59 Million USD | 15.34% |
| 2006 Q4 | -17.75 Million USD | -30.59% |
| 2006 FY | -17.75 Million USD | -15.15% |
| 2006 Q1 | -16.86 Million USD | -9.39% |
| 2005 FY | -15.42 Million USD | -34.4% |
| 2005 Q4 | -15.42 Million USD | -45.46% |
| 2005 Q3 | -10.6 Million USD | 13.81% |
| 2005 Q2 | -12.3 Million USD | 10.18% |
| 2005 Q1 | -13.69 Million USD | -19.36% |
| 2004 Q4 | -11.47 Million USD | 1.96% |
| 2004 Q2 | -13.73 Million USD | 11.87% |
| 2004 Q1 | -15.58 Million USD | -36.82% |
| 2004 Q3 | -11.7 Million USD | 14.8% |
| 2004 FY | -11.47 Million USD | -0.72% |
| 2003 Q3 | -10.64 Million USD | 14.03% |
| 2003 Q1 | -13.31 Million USD | -3.24% |
| 2003 FY | -11.39 Million USD | 11.67% |
| 2003 Q2 | -12.38 Million USD | 6.99% |
| 2003 Q4 | -11.39 Million USD | -7.0% |
| 2002 Q1 | -10.75 Million USD | -10.37% |
| 2002 Q4 | -12.89 Million USD | -14.21% |
| 2002 Q3 | -11.29 Million USD | 12.05% |
| 2002 Q2 | -12.83 Million USD | -19.42% |
| 2002 FY | -12.89 Million USD | -32.4% |
| 2001 Q1 | -9.7 Million USD | 14.59% |
| 2001 Q2 | -8.69 Million USD | 10.42% |
| 2001 Q3 | -7.58 Million USD | 12.76% |
| 2001 Q4 | -9.74 Million USD | -28.42% |
| 2001 FY | -9.74 Million USD | 14.3% |
| 2000 Q4 | -11.36 Million USD | -12.45% |
| 2000 Q2 | -8.21 Million USD | 32.15% |
| 2000 Q1 | -12.1 Million USD | 13.53% |
| 2000 FY | -11.36 Million USD | 18.82% |
| 2000 Q3 | -10.1 Million USD | -23.05% |
| 1999 Q4 | -14 Million USD | -4.48% |
| 1999 Q3 | -13.4 Million USD | 8.84% |
| 1999 Q2 | -14.7 Million USD | 37.97% |
| 1999 FY | -14 Million USD | 50.53% |
| 1999 Q1 | -23.7 Million USD | 16.25% |
| 1998 Q2 | -28.9 Million USD | 10.53% |
| 1998 Q1 | -32.3 Million USD | -26.67% |
| 1998 Q3 | -26.7 Million USD | 7.61% |
| 1998 FY | -28.3 Million USD | -10.98% |
| 1998 Q4 | -28.3 Million USD | -5.99% |
| 1997 Q3 | -7.7 Million USD | -16.67% |
| 1997 Q1 | -9 Million USD | -265.85% |
| 1997 FY | -25.5 Million USD | -6275.0% |
| 1997 Q2 | -6.6 Million USD | 26.67% |
| 1997 Q4 | -25.5 Million USD | -231.17% |
| 1996 Q4 | -2.46 Million USD | 0.0% |
| 1996 FY | -400 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 95.582% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 303.94% |
| Embecta Corp. | 1.31 Billion USD | 98.534% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 95.556% |
| PainReform Ltd. | -7.95 Million USD | 341.899% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 223.002% |
| SCYNEXIS, Inc. | -19.35 Million USD | 199.385% |
| Journey Medical Corporation | -9.7 Million USD | 298.074% |
| Safety Shot Inc | -2.28 Million USD | 941.85% |
| Alpha Teknova, Inc. | 1.97 Million USD | -874.215% |
| Bright Green Corporation | 1.84 Million USD | -944.185% |
| Procaps Group, S.A. | 242.93 Million USD | 92.084% |
| Alvotech | 1.06 Billion USD | 98.193% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 79.586% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 74.342% |
| Cosmos Health Inc. | 8.59 Million USD | -123.857% |
| Dynavax Technologies Corporation | 106.63 Million USD | 81.966% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 95.807% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 114.699% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 223.002% |
| Theratechnologies Inc. | 24.87 Million USD | 22.677% |
| Harrow Health, Inc. | 116.41 Million USD | 83.481% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 863.135% |
| Biofrontera Inc. | 4.05 Million USD | -374.137% |
| DURECT Corporation | -7.65 Million USD | 351.254% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 157.36% |
| Cronos Group Inc. | -663.32 Million USD | 102.899% |
| OptiNose, Inc. | 58.06 Million USD | 66.88% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 96.915% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 231.972% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 470.823% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -28.096% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 402.391% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -17896.612% |
| Radius Health, Inc. | 359.28 Million USD | 94.647% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -9651.583% |
| Phibro Animal Health Corporation | 454.84 Million USD | 95.772% |
| Procaps Group S.A. | 242.93 Million USD | 92.084% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -422.866% |
| Viatris Inc. | 17.13 Billion USD | 99.888% |
| Rockwell Medical, Inc. | 4.45 Million USD | -331.575% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 494.32% |
| SIGA Technologies, Inc. | -148.68 Million USD | 112.934% |
| Tilray Brands, Inc. | 158.97 Million USD | 87.903% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 84.224% |
| Shineco, Inc. | 29.29 Million USD | 34.343% |
| PetIQ, Inc. | 351.93 Million USD | 94.536% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 762.812% |
| Incannex Healthcare Limited | -5.48 Million USD | 450.611% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 89.153% |
| Alimera Sciences, Inc. | 55.3 Million USD | 65.23% |
| Silver Spike Investment Corp. | -32.61 Million USD | 158.97% |
| Assertio Holdings, Inc. | -32.52 Million USD | 159.12% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 1391.779% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 480.03% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 499.481% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 334.14% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -356.035% |
| Hempacco Co., Inc. | 13.61 Million USD | -41.252% |
| Talphera, Inc. | -5.72 Million USD | 436.148% |
| Alvotech | 1.06 Billion USD | 98.193% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -169.153% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 119.885% |
| Currenc Group, Inc. | -16.57 Million USD | 216.037% |
| Kamada Ltd. | -46.43 Million USD | 141.418% |
| Indivior PLC | -33.95 Million USD | 156.642% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -7280.245% |
| Flora Growth Corp. | -713 Thousand USD | 2797.195% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 334.14% |
| Evolus, Inc. | 63.7 Million USD | 69.814% |
| HUTCHMED (China) Limited | -197.45 Million USD | 109.739% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 95.986% |
| Akanda Corp. | 3.9 Million USD | -392.482% |